CASE ON0146a

CERTIFICATE OF MAILING

hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-2450.

Signature

Keith R. Lange

Type or print name

December 12, 2003

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1645

ROSOK ET AL.

Examiner: S. DEVI

APPLICATION NO: 08/905,293

FILED: AUGUST 1, 1997

FOR: A METHOD FOR INHIBITING IMMUNOGLOBULIN-INDUCED

TOXICITY RESULTING FROM THE USE OF IMMUNOGLOBULINS

IN THERAPY AND IN VIVO DIAGNOSIS

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a search report in a corresponding European application. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

OFF 1 5 2003 W

Certificate under 37 C.F.R. §1.97(e)(1)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

Respectfully submitted,

Attorney for Applicants

Keith R. Lange

Reg. No. 44,201

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-3883

Date: December 12, 2003

FORM PTO-1449 (REV. 7-85)

DEC 1 5 2003

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION (Us Deveralsheets if necessary)

ATTY. DOCKET NO. ON0146a APPLICATION NO. 08/905,293 **APPLICANT** ROSOK ET AL. **FILING DATE AUGUST 1, 1997**

Group 1645

XAMINER	T	DOCUMENT NUMBER	DATE	NAME	CLA	ASS SUBCLA	ASS F	ILING DATE
INITIAL	AA	DOGGINETY TOMBETT	JAIL	TVAINE				
	AB							 -
	AC							
	AD							
	AE							
	AF			<u> </u>				· · · · · · · · · · · · · · · · · · ·
	AG							
	AH							
	Al							
	AJ							•
	AK							
	AL		<u> </u>					
			FORFIGN	PATENT DOCUMENTS			<u> </u>	
	Τ	DOCUMENT NUMBER	· · · · · · · · · · · · · · · · · · ·			SUBCLASS TRANS		ISLATIO
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	YES	NO
	AM							느
	AN							14
	AO					<u> </u>		1 <u></u>
	AP							
	AQ							
		OTHER DOC	JMENTS (Inc	cluding Author, Title, Date, Pe	rtinent pages, E	itc.)		
	AR	Weiner et al. (1994), Jo Bispecific Antibody The	ournal of Imm erapy" 152:23	unology, "The Role of T 0 85-2392	Cell Activation	in Anti-CD3	x Antit	umor
		i						
<u> </u>	AS							

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.